Home » Topics » BioWorld Science

BioWorld Science
RSS

Patients dosed in phase I/II trial of topical RECCE-327 for infected burn wounds

July 13, 2021

Immunic presents new preclinical and clinical data for IMU-935

July 13, 2021

Qixleef phase II protocol modifications approved

July 13, 2021

Prokineticin-2 as therapeutic target for prevention of neuronal death

July 13, 2021

Aptorum reports further interim phase I data on ALS-4

July 13, 2021

Identification of antivirulence compound ANT-3273 for P. aeruginosa infection

July 13, 2021

Dosing begins in phase I study of CB-010 in B-cell NHL

July 13, 2021

First patient treated in phase I study of INKmune in high-risk MDS

July 13, 2021

Hummingbird and MD Anderson collaborate to advance VISTA antagonist antibody, HMBD-002

July 13, 2021

EscharEx debridement agent demonstrates efficiency, safety in chronic wound study

July 13, 2021

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 21, 2026.
Biohaven reports details on discovery of BHV-2100
BioWorld Science
Transient receptor potential melastatin 3 (TRPM3) is a calcium-permeable TRP channel that is highly expressed in somatosensory neurons, including nociceptors of...
Meta-analysis: Anti-amyloid Alzheimer’s drugs not ‘clinically meaningful’
BioWorld
The ongoing controversy over the effectiveness of anti-amyloid drugs is about to get more heated, after a review of clinical trials showed statistically...
Hengrui discovers new Nav1.8 blockers
BioWorld Science
Researchers from Jiangsu Hengrui Pharmaceuticals Co. Ltd. and Shanghai Hengrui Pharmaceutical Co. Ltd. have patented new sodium channel protein type 10 subunit α...
New GABA(B) receptor PAMs revealed in Addex Pharma patents
BioWorld Science
Addex Pharma SA has disclosed new GABA(B) receptor positive allosteric modulators (PAMs) potentially useful for the treatment of chronic cough, urinary...